Stagno Fabio, Stella Stefania, Spitaleri Antonio, Pennisi Maria Stella, Di Raimondo Francesco, Vigneri Paolo
a Division of Hematology - A.O.U. 'Policlinico - Vittorio Emanuele' , Catania , Italy.
b Department of Clinical and Experimental Medicine , University of Catania , Catania , Italy.
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease, generating unprecedented rates of complete hematologic and cytogenetic responses and sustained reductions in BCR-ABL transcripts. Here, we present an overview on the efficacy and safety of Imatinib and describe the most important clinical studies employing this drug for the frontline treatment of chronic phase CML. We also discuss recent reports describing the long-term outcome of patients receiving Imatinib for their disease. The imminent availability of generic forms of Imatinib coupled with the approval of expensive second-generation tyrosine kinase inhibitors underlines an unmet need for early molecular parameters that may distinguish CML patients likely to benefit from the drug from those that should receive alternative forms of treatment.
酪氨酸激酶抑制剂甲磺酸伊马替尼显著改善了慢性髓性白血病（CML）慢性期患者的临床结局，实现了前所未有的完全血液学和细胞遗传学缓解率，并持续降低BCR-ABL转录本水平。在此，我们概述了伊马替尼的疗效和安全性，并描述了使用该药物一线治疗慢性期CML的最重要临床研究。我们还讨论了近期关于接受伊马替尼治疗患者疾病长期结局的报告。伊马替尼仿制药即将上市，再加上昂贵的第二代酪氨酸激酶抑制剂获批，凸显了对早期分子参数的迫切需求，这些参数可能有助于区分可能从该药物中获益的CML患者与应接受其他治疗形式的患者。
